XTX Topco Ltd Purchases Shares of 23,107 ADMA Biologics, Inc. (NASDAQ:ADMA)

XTX Topco Ltd purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 23,107 shares of the biotechnology company's stock, valued at approximately $396,000.

A number of other hedge funds also recently modified their holdings of ADMA. Barclays PLC raised its position in shares of ADMA Biologics by 192.2% during the third quarter. Barclays PLC now owns 528,629 shares of the biotechnology company's stock worth $10,567,000 after purchasing an additional 347,692 shares during the period. Franklin Resources Inc. raised its position in shares of ADMA Biologics by 19.4% during the third quarter. Franklin Resources Inc. now owns 167,644 shares of the biotechnology company's stock worth $3,351,000 after purchasing an additional 27,180 shares during the period. B. Riley Wealth Advisors Inc. acquired a new stake in shares of ADMA Biologics during the third quarter worth about $368,000. Lord Abbett & CO. LLC acquired a new stake in ADMA Biologics in the 3rd quarter valued at approximately $61,858,000. Finally, Principal Financial Group Inc. raised its position in ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock valued at $23,872,000 after buying an additional 1,059,394 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Stock Up 12.1 %

ADMA Biologics stock traded up $2.65 during midday trading on Monday, reaching $24.51. The stock had a trading volume of 10,253,257 shares, compared to its average volume of 3,671,345. The firm's fifty day simple moving average is $18.97 and its 200-day simple moving average is $18.33. ADMA Biologics, Inc. has a 1-year low of $6.49 and a 1-year high of $25.67. The stock has a market capitalization of $5.82 billion, a P/E ratio of 87.54 and a beta of 0.53. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.